Prothena (PRTA) Financials

$9.59 -0.17 (-1.74%)

Closing price 05/18/2026 04:00 PM Eastern

Extended Trading

$9.85 +0.26 (+2.66%)

As of 05/18/2026 04:10 PM Eastern

Annual Income Statements for Prothena

This table shows Prothena's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-117	-147	-122
Consolidated Net Income / (Loss)	-117	-147	-122
Net Income / (Loss) Continuing Operations	-117	-147	-122
Total Pre-Tax Income	-126	-160	-129
Total Operating Income	-132	-191	-155
Total Gross Profit	54	91	135
Total Revenue	54	91	135
Operating Revenue	54	91	135
Total Cost of Revenue	0.00	0.00	0.00
Total Operating Expenses	185	282	290
Selling, General & Admin Expense	50	62	67
Research & Development Expense	136	221	223
Total Other Income / (Expense), net	5.95	31	26
Interest Expense	-6.35	-31	-26
Other Income / (Expense), net	-0.40	-0.46	-0.19
Income Tax Expense	-8.66	-13	-6.62
Basic Earnings per Share	($2.47)	($2.76)	($2.27)
Weighted Average Basic Shares Outstanding	47.37M	53.22M	53.77M
Diluted Earnings per Share	($2.47)	($2.76)	($2.27)
Weighted Average Diluted Shares Outstanding	47.37M	53.22M	53.77M
Weighted Average Basic & Diluted Shares Outstanding	52.56M	53.72M	53.83M

This table shows Prothena's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-46	6.35	-47	-55	22	-67	-72	67	-59	-58
Consolidated Net Income / (Loss)	-46	6.35	-47	-55	22	-67	-72	67	-59	-58
Net Income / (Loss) Continuing Operations	-46	6.35	-47	-55	22	-67	-72	67	-59	-58
Total Pre-Tax Income	-48	3.35	-50	-59	19	-71	-74	65	-60	-60
Total Operating Income	-50	-0.07	-56	-67	10	-79	-82	58	-67	-65
Total Gross Profit	1.52	50	2.17	4.02	85	0.32	0.05	132	0.97	2.12
Total Revenue	1.52	50	2.17	4.02	85	0.32	0.05	132	0.97	2.12
Operating Revenue	1.52	50	2.17	4.02	85	0.32	0.05	132	0.97	2.12
Total Operating Expenses	52	50	58	71	75	79	82	74	67	67
Selling, General & Admin Expense	12	13	14	15	17	17	17	16	17	17
Research & Development Expense	40	37	45	56	58	62	64	58	51	50
Total Other Income / (Expense), net	1.92	3.42	6.55	7.60	8.51	7.90	7.09	6.47	6.68	5.40
Interest Expense	-1.91	-3.74	-6.69	-7.70	-8.52	-8.10	-7.17	-6.52	-6.74	-5.39
Other Income / (Expense), net	0.00	-0.33	-0.14	-0.10	-0.02	-0.21	-0.08	-0.05	-0.07	0.01
Income Tax Expense	-2.65	-3.00	-2.91	-4.31	-3.09	-3.14	-2.20	-2.04	-0.84	-1.55
Basic Earnings per Share	($0.97)	$0.16	($0.89)	($1.03)	$0.41	($1.25)	($1.34)	$1.24	($1.10)	($1.07)
Weighted Average Basic Shares Outstanding	46.99M	47.37M	52.50M	53.12M	53.56M	53.22M	53.71M	53.77M	53.79M	53.77M
Diluted Earnings per Share	($0.97)	$0.16	($0.89)	($1.03)	$0.38	($1.22)	($1.34)	$1.22	($1.10)	($1.05)
Weighted Average Diluted Shares Outstanding	46.99M	47.37M	52.50M	53.12M	58.00M	53.22M	53.71M	55.04M	53.79M	53.77M
Weighted Average Basic & Diluted Shares Outstanding	48.38M	52.56M	52.75M	53.54M	53.67M	53.72M	53.77M	53.78M	53.81M	53.83M

This table details how cash moves in and out of Prothena's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	132	-92	-149
Net Cash From Operating Activities	-109	-134	-150
Net Cash From Continuing Operating Activities	-109	-134	-150
Net Income / (Loss) Continuing Operations	-117	-147	-122
Consolidated Net Income / (Loss)	-117	-147	-122
Depreciation Expense	0.74	0.93	0.89
Amortization Expense	6.00	7.48	2.69
Non-Cash Adjustments To Reconcile Net Income	25	35	44
Changes in Operating Assets and Liabilities, net	-24	-30	-75
Net Cash From Investing Activities	-0.46	-2.77	-0.30
Net Cash From Continuing Investing Activities	-0.46	-2.77	-0.30
Purchase of Property, Plant & Equipment	-0.46	-2.81	-0.30
Sale of Property, Plant & Equipment	0.00	0.04	0.00
Net Cash From Financing Activities	241	45	1.55
Net Cash From Continuing Financing Activities	241	45	1.55
Issuance of Common Equity	173	21	0.00
Other Financing Activities, net	69	24	1.55
Cash Income Taxes Paid	2.66	1.55	3.17

This table details how cash moves in and out of Prothena's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Change in Cash & Equivalents	-13	216	-24	-27	12	-52	-72	16	-45	-48
Net Cash From Operating Activities	-31	-4.98	-47	-45	9.52	-51	-73	16	-45	-48
Net Cash From Continuing Operating Activities	-31	-4.98	-47	-45	9.52	-51	-74	16	-45	-48
Net Income / (Loss) Continuing Operations	-46	6.35	-47	-55	22	-67	-72	67	-59	-58
Consolidated Net Income / (Loss)	-46	6.35	-47	-55	22	-67	-72	67	-59	-58
Depreciation Expense	0.18	0.20	0.20	0.22	0.23	0.28	0.22	0.23	0.23	0.22
Amortization Expense	1.53	1.53	1.56	1.58	2.08	2.26	-	-	0.67	0.69
Non-Cash Adjustments To Reconcile Net Income	6.42	5.87	7.20	8.50	9.33	9.55	12	11	10	9.87
Changes in Operating Assets and Liabilities, net	6.46	-19	-9.56	-0.63	-24	4.35	-14	-63	2.53	-0.60
Net Cash From Investing Activities	-0.13	-0.15	-0.05	-0.77	-0.44	-1.51	-0.10	-0.14	-0.01	-0.04
Net Cash From Continuing Investing Activities	-0.13	-0.15	-0.05	-0.77	-0.44	-1.51	-0.10	-0.14	-0.01	-0.04
Purchase of Property, Plant & Equipment	-0.13	-0.15	-0.05	-0.77	-0.44	-1.55	-0.10	-0.14	-0.01	-0.04
Net Cash From Financing Activities	18	221	23	19	2.71	0.48	0.84	0.44	0.33	-0.06
Net Cash From Continuing Financing Activities	18	221	23	19	2.71	0.48	0.89	0.39	0.33	-0.06
Other Financing Activities, net	18	48	2.56	19	2.71	0.48	0.89	0.39	0.33	-0.06
Cash Income Taxes Paid	0.75	0.29	0.00	0.33	0.05	1.17	0.02	1.56	0.84	0.76

This table presents Prothena's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Total Assets	758	696	547
Total Current Assets	719	639	485
Cash & Equivalents	710	619	471
Restricted Cash	0.00	1.35	0.00
Accounts Receivable	0.00	5.16	0.00
Prepaid Expenses	8.69	14	14
Plant, Property, & Equipment, net	1.73	3.84	3.08
Total Noncurrent Assets	37	53	59
Noncurrent Deferred & Refundable Income Taxes	18	34	43
Other Noncurrent Operating Assets	19	19	15
Total Liabilities & Shareholders' Equity	758	696	547
Total Liabilities	136	135	60
Total Current Liabilities	50	57	49
Accounts Payable	9.27	25	7.77
Accrued Expenses	11	15	13
Current Deferred Revenue	11	0.00	8.85
Other Current Liabilities	19	17	18
Total Noncurrent Liabilities	86	78	12
Noncurrent Deferred Revenue	85	67	3.45
Other Noncurrent Operating Liabilities	0.55	11	8.23
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	622	561	487
Total Preferred & Common Equity	622	561	487
Total Common Equity	622	561	487
Common Stock	1,455	1,541	1,589
Retained Earnings	-833	-980	-1,102
Other Equity Adjustments	0.00	0.00	0.00

This table presents Prothena's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024
Total Assets	554	742	721	747	623	646	595
Total Current Assets	525	700	677	691	566	586	535
Cash & Equivalents	496	686	659	671	547	564	519
Restricted Cash	-	-	1.35	1.35	1.35	0.00	0.00
Accounts Receivable	-	-	0.52	5.16	0.00	0.00	0.00
Prepaid Expenses	29	14	16	13	18	22	16
Plant, Property, & Equipment, net	2.00	1.92	2.17	2.43	3.67	3.49	3.25
Total Noncurrent Assets	28	39	41	54	54	56	57
Noncurrent Deferred & Refundable Income Taxes	15	21	26	30	37	39	41
Other Noncurrent Operating Assets	13	18	15	24	17	17	16
Total Liabilities & Shareholders' Equity	554	742	721	747	623	646	595
Total Liabilities	150	134	139	130	121	64	61
Total Current Liabilities	51	49	72	53	43	47	46
Accounts Payable	9.79	13	14	19	14	9.29	10
Accrued Expenses	12	14	19	18	17	16	10
Current Deferred Revenue	9.67	9.32	25	0.32	0.00	8.03	8.83
Other Current Liabilities	20	13	14	16	12	14	17
Total Noncurrent Liabilities	99	85	67	76	78	17	14
Noncurrent Deferred Revenue	97	85	67	67	67	7.37	5.59
Other Noncurrent Operating Liabilities	2.20	0.00	0.00	8.92	10	9.54	8.88
Commitments & Contingencies	-	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	405	607	582	617	502	582	534
Total Preferred & Common Equity	405	607	582	617	502	582	534
Total Common Equity	405	607	582	617	502	582	534
Common Stock	1,244	1,487	1,516	1,530	1,555	1,567	1,579
Retained Earnings	-839	-880	-934	-913	-1,052	-985	-1,044
Other Equity Adjustments	0.00	0.00	0.00	0.00	0.00	0.00	0.00

This table displays calculated financial ratios and metrics derived from Prothena's official financial filings.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-
Revenue Growth	-73.13%	69.50%	47.92%
EBITDA Growth	-259.14%	-46.22%	17.44%
EBIT Growth	-283.58%	-45.12%	19.19%
NOPAT Growth	-237.40%	-45.21%	19.09%
Net Income Growth	-274.62%	-25.72%	16.81%
EPS Growth	-278.99%	-11.74%	17.75%
Operating Cash Flow Growth	-217.51%	-23.05%	-12.06%
Free Cash Flow Firm Growth	-273.39%	-39.81%	-11.81%
Invested Capital Growth	21.84%	33.44%	126.42%
Revenue Q/Q Growth	945.89%	-35.19%	1.36%
EBITDA Q/Q Growth	20.73%	-73.42%	7.47%
EBIT Q/Q Growth	19.86%	-69.20%	8.21%
NOPAT Q/Q Growth	20.06%	-69.67%	8.10%
Net Income Q/Q Growth	25.26%	-100.85%	7.22%
EPS Q/Q Growth	19.02%	-100.00%	6.97%
Operating Cash Flow Q/Q Growth	13.84%	-52.44%	2.13%
Free Cash Flow Firm Q/Q Growth	12.76%	-42.26%	2.82%
Invested Capital Q/Q Growth	2.88%	-6.90%	2.90%
Profitability Metrics	-	-	-
Gross Margin	100.00%	100.00%	100.00%
EBITDA Margin	-232.28%	-200.37%	-111.84%
Operating Margin	-244.05%	-209.08%	-114.36%
EBIT Margin	-244.79%	-209.58%	-114.49%
Profit (Net Income) Margin	-216.95%	-160.92%	-90.49%
Tax Burden Percent	93.11%	91.62%	94.87%
Interest Burden Percent	95.19%	83.80%	83.32%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%
Return on Equity (ROE)	-21.50%	-24.85%	-23.34%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	-1,174.85%
Operating Return on Assets (OROA)	-19.30%	-26.33%	-24.89%
Return on Assets (ROA)	-17.11%	-20.22%	-19.67%
Return on Common Equity (ROCE)	-21.50%	-24.85%	-23.34%
Return on Equity Simple (ROE_SIMPLE)	-18.80%	-26.19%	-25.12%
Net Operating Profit after Tax (NOPAT)	-92	-134	-108
NOPAT Margin	-170.84%	-146.36%	-80.05%
Net Nonoperating Expense Percent (NNEP)	-3.86%	-2.00%	-2.59%
Return On Investment Capital (ROIC_SIMPLE)	-14.80%	-23.82%	-22.22%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	92.57%	67.68%	49.72%
R&D to Revenue	251.48%	241.40%	164.64%
Operating Expenses to Revenue	344.05%	309.08%	214.36%
Earnings before Interest and Taxes (EBIT)	-132	-191	-155
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-125	-183	-151
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	4.69	3.47	1.53
Price to Tangible Book Value (P/TBV)	4.69	3.47	1.53
Price to Revenue (P/Rev)	54.07	21.34	5.51
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	17.63
Enterprise Value to Revenue (EV/Rev)	40.89	14.56	2.03
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00
Financial Leverage	-1.19	-1.12	-1.04
Leverage Ratio	1.26	1.23	1.19
Compound Leverage Factor	1.20	1.03	0.99
Debt to Total Capital	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00
Altman Z-Score	11.88	6.92	4.88
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	14.34	11.24	10.01
Quick Ratio	14.17	10.97	9.72
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-117	-163	-183
Operating Cash Flow to CapEx	-23,452.80%	-4,828.92%	-50,352.35%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00
Efficiency Ratios	-	-	-
Asset Turnover	0.08	0.13	0.22
Accounts Receivable Turnover	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00
Fixed Asset Turnover	28.80	32.83	39.08
Accounts Payable Turnover	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-
Invested Capital	-88	-59	16
Invested Capital Turnover	-0.54	-1.24	-6.25
Increase / (Decrease) in Invested Capital	25	30	74
Enterprise Value (EV)	2,204	1,330	274
Market Capitalization	2,915	1,950	745
Book Value per Share	$12.86	$10.46	$9.05
Tangible Book Value per Share	$12.86	$10.46	$9.05
Total Capital	622	561	487
Total Debt	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00
Net Debt	-710	-620	-471
Capital Expenditures (CapEx)	0.46	2.77	0.30
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-41	-38	-34
Debt-free Net Working Capital (DFNWC)	669	582	437
Net Working Capital (NWC)	669	582	437
Net Nonoperating Expense (NNE)	25	13	14
Net Nonoperating Obligations (NNO)	-710	-620	-471
Total Depreciation and Amortization (D&A)	6.74	8.41	3.59
Debt-free, Cash-free Net Working Capital to Revenue	-76.90%	-41.36%	-25.51%
Debt-free Net Working Capital to Revenue	1,240.98%	637.40%	323.26%
Net Working Capital to Revenue	1,240.98%	637.40%	323.26%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($2.47)	($2.76)	($2.27)
Adjusted Weighted Average Basic Shares Outstanding	47.37M	53.22M	53.77M
Adjusted Diluted Earnings per Share	($2.47)	($2.76)	($2.27)
Adjusted Weighted Average Diluted Shares Outstanding	47.37M	53.22M	53.77M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	52.56M	53.72M	53.83M
Normalized Net Operating Profit after Tax (NOPAT)	-92	-134	-108
Normalized NOPAT Margin	-170.84%	-146.36%	-80.05%
Pre Tax Income Margin	-233.01%	-175.64%	-95.39%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Prothena's official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-98.91%	4,159.64%	88.12%	206.33%	5,494.33%	-99.37%	-97.69%	3,184.75%	-98.86%	571.84%
EBITDA Growth	-143.84%	104.23%	-50.41%	-55.95%	125.93%	-5,836.52%	-48.77%	190.37%	-621.08%	16.02%
EBIT Growth	-146.10%	98.79%	-48.54%	-54.13%	120.45%	-19,629.32%	-44.52%	187.58%	-746.84%	17.57%
NOPAT Growth	-132.24%	99.41%	-48.44%	-53.91%	134.07%	-40,116.93%	-44.75%	229.34%	-487.93%	17.34%
Net Income Growth	-141.89%	119.14%	-29.14%	-32.37%	147.87%	-1,162.78%	-54.15%	222.51%	-369.32%	14.11%
EPS Growth	-145.54%	138.10%	-14.10%	-17.05%	139.18%	-862.50%	-50.56%	218.45%	-389.47%	13.93%
Operating Cash Flow Growth	-127.80%	77.84%	-26.84%	-27.41%	130.54%	-925.68%	-53.93%	135.52%	-574.79%	6.40%
Free Cash Flow Firm Growth	-147.87%	-8.70%	-101.02%	-66.00%	55.54%	-240.42%	-39.56%	47.50%	-387.06%	-41.74%
Invested Capital Growth	17.01%	21.84%	24.33%	22.38%	39.52%	33.44%	42.29%	122.58%	127.44%	126.42%
Revenue Q/Q Growth	15.63%	3,190.90%	-95.66%	85.29%	2,011.62%	-99.63%	-84.18%	263,928.00%	-99.27%	118.87%
EBITDA Q/Q Growth	-17.00%	102.73%	-4,219.50%	-18.45%	119.45%	-704.32%	-6.84%	171.95%	-212.18%	2.61%
EBIT Q/Q Growth	-16.48%	99.21%	-14,051.88%	-17.95%	115.45%	-864.79%	-3.66%	171.47%	-214.15%	2.54%
NOPAT Q/Q Growth	-16.49%	99.61%	-28,750.78%	-18.07%	125.78%	-557.93%	-3.84%	205.51%	-177.32%	2.43%
Net Income Q/Q Growth	-10.96%	113.87%	-838.13%	-16.50%	140.13%	-408.01%	-7.06%	192.59%	-188.21%	1.77%
EPS Q/Q Growth	-10.23%	116.49%	-656.25%	-15.73%	136.89%	-421.05%	-9.84%	191.04%	-190.16%	4.55%
Operating Cash Flow Q/Q Growth	11.62%	84.03%	-853.74%	5.33%	121.18%	-636.28%	-43.13%	121.85%	-383.14%	-5.72%
Free Cash Flow Firm Q/Q Growth	-29.13%	53.93%	-160.87%	-6.96%	65.41%	-252.76%	-6.95%	59.76%	-220.87%	-2.66%
Invested Capital Q/Q Growth	10.36%	2.88%	10.85%	-0.01%	30.16%	-6.90%	22.70%	139.14%	-15.14%	2.90%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
EBITDA Margin	-3,204.75%	2.66%	-2,522.22%	-1,612.34%	14.85%	-24,107.91%	-162,780.00%	44.36%	-6,771.86%	-3,013.42%
Operating Margin	-3,317.86%	-0.14%	-2,596.82%	-1,654.74%	12.15%	-24,846.52%	-163,056.00%	44.22%	-6,857.01%	-3,056.85%
EBIT Margin	-3,317.73%	-0.80%	-2,603.32%	-1,657.15%	12.13%	-24,911.39%	-163,210.00%	44.18%	-6,863.81%	-3,056.43%
Profit (Net Income) Margin	-3,016.74%	12.72%	-2,160.63%	-1,358.42%	25.81%	-21,353.16%	-144,478.00%	50.67%	-6,082.58%	-2,729.91%
Tax Burden Percent	94.52%	189.81%	94.15%	92.69%	116.43%	95.55%	97.04%	103.14%	98.60%	97.40%
Interest Burden Percent	96.20%	-838.35%	88.15%	88.44%	182.79%	89.71%	91.22%	111.18%	89.87%	91.70%
Effective Tax Rate	0.00%	-89.81%	0.00%	0.00%	-16.43%	0.00%	0.00%	-3.14%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-34.96%	-21.50%	-24.38%	-28.49%	-14.33%	-24.85%	-31.07%	-8.75%	-22.90%	-23.34%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-902.20%	-1,244.02%	-1,174.85%
Operating Return on Assets (OROA)	-28.81%	-0.06%	-216.14%	-150.36%	2.63%	-3,129.99%	-21,346.53%	14.05%	-1,363.89%	-664.42%
Return on Assets (ROA)	-26.19%	1.00%	-179.39%	-123.26%	5.59%	-2,682.92%	-18,896.53%	16.11%	-1,208.65%	-593.44%
Return on Common Equity (ROCE)	-34.96%	-21.50%	-24.38%	-28.49%	-14.33%	-24.85%	-31.07%	-8.75%	-22.90%	-23.34%
Return on Equity Simple (ROE_SIMPLE)	-38.67%	0.00%	-20.99%	-24.22%	-11.86%	0.00%	-34.32%	-8.75%	-24.67%	0.00%
Net Operating Profit after Tax (NOPAT)	-35	-0.14	-39	-47	12	-55	-57	60	-47	-45
NOPAT Margin	-2,322.50%	-0.27%	-1,817.77%	-1,158.32%	14.14%	-17,392.56%	-114,139.20%	45.61%	-4,799.91%	-2,139.80%
Net Nonoperating Expense Percent (NNEP)	-1.92%	1.01%	-1.21%	-1.38%	1.70%	-1.88%	-2.46%	1.09%	-2.09%	-2.30%
Return On Investment Capital (ROIC_SIMPLE)	-	-0.02%	-	-	-	-9.79%	-	-	-	-9.33%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	790.31%	26.29%	633.38%	361.08%	19.61%	5,360.76%	34,928.00%	12.22%	1,727.84%	793.59%
R&D to Revenue	2,627.55%	73.86%	2,063.44%	1,393.66%	68.24%	19,585.76%	128,228.00%	43.56%	5,229.18%	2,363.26%
Operating Expenses to Revenue	3,417.86%	100.14%	2,696.82%	1,754.74%	87.85%	24,946.52%	163,156.00%	55.78%	6,957.01%	3,156.85%
Earnings before Interest and Taxes (EBIT)	-50	-0.40	-56	-67	10	-79	-82	58	-67	-65
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-49	1.33	-55	-65	13	-76	-81	59	-66	-64
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	7.03	4.69	4.19	6.19	4.19	3.47	2.65	1.91	1.68	1.53
Price to Tangible Book Value (P/TBV)	7.03	4.69	4.19	6.19	4.19	3.47	2.65	1.91	1.68	1.53
Price to Revenue (P/Rev)	551.99	54.07	46.39	62.50	18.32	21.34	14.89	5.11	6.75	5.51
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	30.67	25.20	17.63
Enterprise Value to Revenue (EV/Rev)	455.82	40.89	33.90	51.04	13.55	14.56	8.76	2.51	2.85	2.03
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-1.22	-1.19	-1.17	-1.18	-1.14	-1.12	-1.11	-1.05	-1.03	-1.04
Leverage Ratio	1.33	1.26	1.26	1.28	1.27	1.23	1.23	1.17	1.17	1.19
Compound Leverage Factor	1.28	-10.54	1.11	1.14	2.33	1.10	1.12	1.31	1.05	1.09
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	10.01	12.45	10.61	14.52	11.50	7.46	4.96	9.96	7.25	5.42
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	10.37	14.34	14.33	9.46	12.94	11.24	13.08	12.54	11.52	10.01
Quick Ratio	9.80	14.17	14.04	9.22	12.67	10.97	12.63	12.07	11.19	9.72
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-54	-25	-65	-69	-24	-85	-90	-36	-117	-120
Operating Cash Flow to CapEx	-23,974.62%	-3,295.36%	-98,870.83%	-5,827.11%	2,153.17%	-3,294.90%	-70,923.30%	11,160.14%	-502,066.67%	-111,097.67%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.01	0.08	0.08	0.09	0.22	0.13	0.13	0.32	0.20	0.22
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	2.62	28.80	28.99	28.59	63.65	32.83	31.90	76.82	46.90	39.08
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	-91	-88	-79	-79	-55	-59	-45	18	15	16
Invested Capital Turnover	-0.05	-0.54	-0.60	-0.64	-1.93	-1.24	-1.44	-7.12	-6.68	-6.25
Increase / (Decrease) in Invested Capital	19	25	25	23	36	30	33	97	70	74
Enterprise Value (EV)	2,349	2,204	1,862	2,941	1,911	1,330	781	546	380	274
Market Capitalization	2,845	2,915	2,548	3,602	2,583	1,950	1,329	1,110	900	745
Book Value per Share	$8.62	$12.86	$11.56	$11.03	$11.53	$10.46	$9.35	$10.82	$9.94	$9.05
Tangible Book Value per Share	$8.62	$12.86	$11.56	$11.03	$11.53	$10.46	$9.35	$10.82	$9.94	$9.05
Total Capital	405	622	607	582	617	561	502	582	534	487
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-496	-710	-686	-660	-672	-620	-548	-564	-519	-471
Capital Expenditures (CapEx)	0.13	0.15	0.05	0.77	0.44	1.55	0.10	0.14	0.01	0.04
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-22	-41	-35	-55	-35	-38	-25	-25	-31	-34
Debt-free Net Working Capital (DFNWC)	474	669	651	606	637	582	523	539	489	437
Net Working Capital (NWC)	474	669	651	606	637	582	523	539	489	437
Net Nonoperating Expense (NNE)	11	-6.49	7.44	8.04	-9.91	13	15	-6.67	12	13
Net Nonoperating Obligations (NNO)	-496	-710	-686	-660	-672	-620	-548	-564	-519	-471
Total Depreciation and Amortization (D&A)	1.71	1.73	1.76	1.80	2.31	2.54	0.22	0.23	0.89	0.91
Debt-free, Cash-free Net Working Capital to Revenue	-420.33%	-76.90%	-63.23%	-95.31%	-24.84%	-41.36%	-28.30%	-11.46%	-23.02%	-25.51%
Debt-free Net Working Capital to Revenue	9,196.04%	1,240.98%	1,186.17%	1,050.77%	452.01%	637.40%	585.54%	248.21%	366.38%	323.26%
Net Working Capital to Revenue	9,196.04%	1,240.98%	1,186.17%	1,050.77%	452.01%	637.40%	585.54%	248.21%	366.38%	323.26%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.97)	$0.16	($0.89)	($1.03)	$0.41	($1.25)	($1.34)	$1.24	($1.10)	($1.07)
Adjusted Weighted Average Basic Shares Outstanding	46.99M	47.37M	52.50M	53.12M	53.56M	53.22M	53.71M	53.77M	53.79M	53.77M
Adjusted Diluted Earnings per Share	($0.97)	$0.16	($0.89)	($1.03)	$0.38	($1.22)	($1.34)	$1.22	($1.10)	($1.05)
Adjusted Weighted Average Diluted Shares Outstanding	46.99M	47.37M	52.50M	53.12M	58.00M	53.22M	53.71M	55.04M	53.79M	53.77M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	48.38M	52.56M	52.75M	53.54M	53.67M	53.72M	53.77M	53.78M	53.81M	53.83M
Normalized Net Operating Profit after Tax (NOPAT)	-35	-0.05	-39	-47	7.22	-55	-57	41	-47	-45
Normalized NOPAT Margin	-2,322.50%	-0.10%	-1,817.77%	-1,158.32%	8.50%	-17,392.56%	-114,139.20%	30.95%	-4,799.91%	-2,139.80%
Pre Tax Income Margin	-3,191.63%	6.70%	-2,294.88%	-1,465.56%	22.17%	-22,347.47%	-148,880.00%	49.12%	-6,168.66%	-2,802.68%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials Breakdown Chart

Key Financial Trends

Here is a concise trend overview of Prothena's quarterly results based on the most recent four years of data provided (covering 2022 through 2024), using the quarterly income statements, cash flow statements, and balance sheets. The focus is on the strongest trends that may matter to retail investors.

In Q2 2024, Prothena posted a notable upturn: operating revenue about $132.0 million and net income around $66.9 million, with basic earnings per share of $1.24 and diluted EPS of $1.22.
Cash flow from continuing operating activities in Q2 2024 was positive, about $16.4 million, marking a rare period of quarterly cash generation from operations amid a history of cash burn in other quarters.
Q2 2024 also showed solid profitability on a pre-tax basis: Total Pre-Tax Income roughly $64.8 million and other income (net) around $6.5 million, supporting a strong quarterly bottom line.\n
The balance sheet shows substantial liquidity in 2024, with cash & equivalents typically in the mid-to-high hundreds of millions (e.g., about $564 million in Q2 2024 and $519 million in Q3 2024; cash was around $670.9 million in Q4 2023), providing runway for ongoing R&D and clinical efforts.
Equity remains robust and relatively stable, with Total Common Equity in the 580–620 million range across the recent quarters (e.g., about $581.9 million in Q3 2024), supporting a solid equity base for the company.
R&D expense remains a major ongoing cost, typically in the $50–66 million per quarter range, indicating continued heavy investment in pipeline development which can pressure short-term margins but may be essential for long-term value creation.
Selling, General & Administrative (SG&A) expenses run in the mid-teens of millions per quarter (roughly $16–17 million), providing a relatively steady overhead profile alongside R&D outlays.
Capital expenditures are modest (PPE purchases are only tens of thousands of dollars per quarter), suggesting limited near-term capital spending and more focus on cash management and clinical development.
Revenue across quarters shows volatility, with a large spike in Q3 2023 and another standout quarter in Q2 2024, but several 2024 quarters report more modest topline levels, reflecting a variable revenue trajectory.
Net income is negative in most quarters outside of Q2 2024 (for example, Q1 2024, Q3 2024, and Q4 2024 all show losses), underscoring ongoing profitability challenges despite the recent quarterly strength.
Accumulated deficits persist, with Retained Earnings reported as negative in multiple periods (e.g., around -$912 million by Q3 2024), contributing to a continuing negative book value trend alongside recurring cash flow weakness in several quarters.

05/19/26 03:29 AM ETAI Generated. May Contain Errors.

Prothena Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Prothena's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

Prothena's net income appears to be on an upward trend, with a most recent value of -$122.31 million in 2024, rising from -$116.95 million in 2022. The previous period was -$147.03 million in 2023. View Prothena's forecast to see where analysts expect Prothena to go next.

Prothena's total operating income in 2024 was -$154.56 million, based on the following breakdown:

Total Gross Profit: $135.16 million
Total Operating Expenses: $289.72 million

Over the last 2 years, Prothena's total revenue changed from $53.91 million in 2022 to $135.16 million in 2024, a change of 150.7%.

Prothena's total liabilities were at $60.18 million at the end of 2024, a 55.4% decrease from 2023, and a 55.7% decrease since 2022.

In the past 2 years, Prothena's cash and equivalents has ranged from $471.39 million in 2024 to $710.41 million in 2022, and is currently $471.39 million as of their latest financial filing in 2024.

Over the last 2 years, Prothena's book value per share changed from 12.86 in 2022 to 9.05 in 2024, a change of -29.6%.

Related Companies

Financial statements for NASDAQ:PRTA last updated on 4/6/2025 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Prothena (PRTA) Financials

Financials Breakdown Chart

Key Financial Trends

Prothena Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Prothena (PRTA) Financials

Annual Income Statements for Prothena

Quarterly Income Statements for Prothena

Annual Cash Flow Statements for Prothena

Quarterly Cash Flow Statements for Prothena

Annual Balance Sheets for Prothena

Quarterly Balance Sheets for Prothena

Annual Metrics And Ratios for Prothena

Quarterly Metrics And Ratios for Prothena

Financials Breakdown Chart

Key Financial Trends

Prothena Financials - Frequently Asked Questions

When does Prothena's financial year end?

How has Prothena's net income changed over the last 2 years?

What is Prothena's operating income?

How has Prothena's revenue changed over the last 2 years?

How much debt does Prothena have?

How much cash does Prothena have?

How has Prothena's book value per share changed over the last 2 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools